Reframing asthma and inhaled corticosteroids (ICS) to modify treatment beliefs: an online randomised controlled trial

C. Katzer (London, United Kingdom), V. Wileman (London, United Kingdom), A. Chan (London, United Kingdom), S. Taylor (London, United Kingdom), R. Horne (London, United Kingdom)

Source: International Congress 2018 – Educational tools to improve your practice
Session: Educational tools to improve your practice
Session type: Oral Presentation
Number: 1644
Disease area: Airway diseases

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Katzer (London, United Kingdom), V. Wileman (London, United Kingdom), A. Chan (London, United Kingdom), S. Taylor (London, United Kingdom), R. Horne (London, United Kingdom). Reframing asthma and inhaled corticosteroids (ICS) to modify treatment beliefs: an online randomised controlled trial. 1644

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Should asthma guidelines be rewritten for initial controller therapy: a 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Rationale of self-education in asthma therapy
Year: 2008

“Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial)
Source: Annual Congress 2013 –Asthma treatment and management in children
Year: 2013


Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial
Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID
Year: 2021



Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma
Source: Eur Respir J 2016; 47: 981-984
Year: 2016


Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice
Source: Annual Congress 2010 - Pharmacological treatment in primary care
Year: 2010


Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials.
Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma
Year: 2020

Self-titration of inhaled corticosteroid and ß2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial
Source: Eur Respir J, 56 (4) 2000170; 10.1183/13993003.00170-2020
Year: 2020



Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial.
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017

Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008


Asthma control with inhaled corticosteroid therapy: A real-world observational study
Source: Annual Congress 2010 - Management of airway disease
Year: 2010

Comparison of an innovative multi-dose inhaler with the attributes of an 'ideal' inhaler: A multicentre randomised controlled trial (RCT)
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014

Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013


Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial
Source: Eur Respir J, 58 (1) 2100130; 10.1183/13993003.00130-2021
Year: 2021



LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015


Effectiveness of a pharmacist intervention for asthma control improvement: randomised controlled trial
Source: Annual Congress 2007 - Delivering respiratory care: the challenges for primary care
Year: 2007


Omalizumab in patients with moderate-to-severe persistent asthma poorly controlled on high-dose inhaled corticosteroids and long-acting beta-agonists: Results of a phase IIIb randomized controlled trial
Source: Annual Congress 2010 - Aspects of severe asthma
Year: 2010


An electronic patient decision aid comparing as-needed budesonide-formoterol combination to regular use of inhaled corticosteroid (ICS) in mild asthma: a rapid-cycle design study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


The Children's Anti-inflammatory Reliever (CARE) study: a protocol for a randomised controlled trial of budesonide-formoterol as sole reliever therapy in children with mild asthma
Source: ERJ Open Res, 7 (4) 00271-2021; 10.1183/23120541.00271-2021
Year: 2021



Maintenance and reliever combination budesonide/formoterol therapy in asthma patients at risk of severe exacerbations: A randomised controlled trial
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013